“2 “Strong Buy” Penny Stocks That Could See Outsized Gains”
May 14, 2021
“GlycoMimetics (GLYC)…
To this end, Jallah rates GLYC a Buy along with a $15 price target. Shares could appreciate by 567%, should the analyst’s thesis play out in the coming months… The company’s progress has attracted 3 unanimous positive reviews from Wall Street, giving it a Strong Buy consensus rating. Based on the $14.50 average price target, the upside potential comes in at 544%…
OcuPhire Pharma (OCUP)…
Do other analysts agree with Newman? They do. Only Buy ratings, 4, in fact, have been issued in the last three months, so the consensus rating is a Strong Buy. The average price target of $23.50 suggests an impressive 458% upside from the share price of $4.21…”
https://finance.yahoo.com/news/2-strong-buy-penny-stocks-151531621.html